Article Sidebar
Views pdf: 59
TREATMENT OUTCOME OF GAMMA KNIFE RADIOSURGERY COMBINED WITH PACLITAXEL-CARBOPLATIN IN BRAIN METASTATIC NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Purpose: This study aims to describe some clinical and subclinical characteristic of brain metastatic non-small cell lung cancer in National cancer hospital between 2020 and 2023, and to evaluate the treatment outcomes of the Paclitaxel-Carboplatin regimen combined with Gamma Knife radiosurgery in this population. Methods: A retrospective study on 66 patients diagnosed with brain metastatic non-small cell lung cancer, who treated with Paclitaxel-Carboplatin and gamma knife radiosurgery in National cancer hospital from 2020 to 2023. Results: The mean age was 59,1 ± 8,4 years old, males accounted for 80,3%. Clinical characteristic: intracranialhypertension (71,2%), dry cough (63,6%), no neurological symptom (18,1%). MRI features: tumor located in hemispheres (81,8%), three tumors (43,9%), above 10mm in diameter of brain metastases (80,3%). The overall response rate (ORR) was 31,8%, the objective cerebral response rate was 72,9%. The disease control rate (DCR) of cerebral lesions was 92,4%. The median progression free survival (PFS) was 7,6 months. The median progression free survival of brain metastases was 10,1 months. Conclusion: Gamma knife radiosurgery combined with Paclitaxel and Carboplatin is effective in treating brain metastases of small cell lung cancer
Article Details
Keywords
non-small cell lung cancer, brain metastases, chemotherapy, gamma knife radiosurgery.
References
2. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45(7):741-744.
3. Edelman MJ, Belani CP, Socinski MA, et al. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5(1):110-116.
4. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A. Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg. 2005;102 Suppl:75-80.
5. Moro-Sibilot D, Smit E, de Castro Carpeno J, et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer Amst Neth. 2015;90(3).
6. Yamamoto M, Serizawa T, Higuchi Y, et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017;99(1):31-40.
7. Zhou C, Wu YL, Chen G, et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(19):2197-2204.